[0029] The invention also features a protein described above for use in promoting local depletion of TGFβ at a tumor.

[0030] The invention also features a protein described above for use in inhibiting SMAD3 phosphorylation in a cell (*e.g.*, a tumor cell or an immune cell).

[0031] The invention also features a protein described above for use in treating cancer or for use in inhibiting tumor growth. The cancer or tumor may be selected from the group consisting of colorectal, breast, ovarian, pancreatic, gastric, prostate, renal, cervical, myeloma, lymphoma, leukemia, thyroid, endometrial, uterine, bladder, neuroendocrine, head and neck, liver, nasopharyngeal, testicular, small cell lung cancer, non-small cell lung cancer, melanoma, basal cell skin cancer, squamous cell skin cancer, dermatofibrosarcoma protuberans, Merkel cell carcinoma, glioblastoma, glioma, sarcoma, mesothelioma, and myelodisplastic syndromes. The use may further include administration of radiation or administration of a chemotherapeutic, a biologic, or a vaccine.

[0032] The invention also features a protein as described herein for use in promoting local depletion of TGFβ, wherein the protein binds TGFβ in solution, binds PD-L1 on a cell surface, and carries the bound TGFβ into the cell. Also disclosed is a method of promoting local depletion of TGFβ. The method includes administering a protein described above, where the protein binds TGFβ in solution, binds PD-L1 on a cell surface, and carries the bound TGFβ into the cell (*e.g.*, a cancer cell).

[0033] The invention also features a protein as described herein for use in inhibiting SMAD3 phosphorylation in a cell. Also disclosed is a method of inhibiting SMAD3 phosphorylation in a cell (*e.g.*, a cancer cell or an immune cell), the method including exposing the cell in the tumor microenvironment to a protein described above.

[0034] The invention also features a protein as described herein for use in inhibiting tumor growth and use of a protein as described herein in the manufacture of a medicament for treating cancer. Also disclosed is a method of inhibiting tumor growth or treating cancer. The method includes exposing the tumor to a protein described above. The method may further include exposing the tumor to radiation or to a chemotherapeutic, a biologic, or a vaccine. In certain embodiments, the tumor or cancer is selected from the group consisting of colorectal, breast, ovarian, pancreatic, gastric, prostate, renal, cervical, myeloma, lymphoma, leukemia, thyroid, endometrial, uterine, bladder, neuroendocrine, head and neck, liver, nasopharyngeal, testicular, small cell lung cancer, non-small cell lung cancer, melanoma, basal cell skin cancer, squamous cell skin cancer, dermatofibrosarcoma protuberans, Merkel cell carcinoma, glioblastoma, glioma, sarcoma, mesothelioma, and myelodisplastic syndromes.

[0035] By "TGFβRII" or "TGFβ Receptor II" is meant a polypeptide having the wild-type human TGFβ Receptor Type 2 Isoform A sequence (*e.g.*, the amino acid sequence of NCBI

protuberans, Merkel cell carcinoma, glioblastoma, glioma, sarcoma, mesothelioma, and myelodisplastic syndromes.

24. A protein according to any one of claims 21-23, wherein the use ~~comprises~~ is to be ~~administration~~ administered ~~of~~with radiation.

25. A protein according to any one of claims 21-24, wherein the use ~~comprises~~ is to be ~~administration~~ administered ~~of~~ with a chemotherapeutic.

26. ~~A method of promoting local depletion of TGFβ, the method comprising administering a~~ A protein according to claim 1, 13, or 14 for use in promoting local depletion of TGFβ, wherein the protein binds TGFβ in solution, binds PD-L1 on a cell surface, and carries the bound TGFβ into the cell.

27. ~~A method of inhibiting SMAD3 phosphorylation in a cell, the method comprising exposing the cell to a~~ A protein according to claim 1, 13, or 14 for use in inhibiting SMAD3 phosphorylation in a cell.

28. A protein for use~~method~~ according to claim 26 or 27, wherein the cell is a cancer cell.

29. ~~A method of inhibiting tumor growth, the method comprising exposing the tumor to a~~ A protein according to claim 1, 13, or 14 for use in inhibiting tumor growth.

30. The ~~method~~ protein for use of claim 29, wherein the use is to be administered with ~~further comprising exposing the tumor to~~ radiation.

31. A ~~method~~ protein for use according to claim 29 or 30, ~~further~~ wherein the use is to be administered with ~~comprising exposing the tumor to~~ a chemotherapeutic.

32. ~~A method of treating cancer, the method comprising administering to a cancer patient~~ Use of a protein according to claim 1, 13, or 14 in the manufacture of a medicament for treating cancer.

33. The ~~method~~ use of claim 32, is to be further provided with ~~comprising~~ exposing the cancer patient to radiation.

34. A ~~method~~ use according to claim 32 or 33, is to be further ~~comprising~~ administer~~eding~~ with a chemotherapeutic.

35. A ~~method~~ use according to any one of claims 29-34, wherein the tumor or cancer is selected from the group consisting of colorectal, breast, ovarian, pancreatic, gastric, prostate, renal, cervical, myeloma, lymphoma, leukemia, thyroid, endometrial, uterine, bladder, neuroendocrine, head and neck, liver, nasopharyngeal, testicular, small cell lung cancer, non-small cell lung cancer, melanoma, basal cell skin cancer, squamous cell skin cancer,